台湾高校在全球排名中的表现：医学领域的学术产出

National Taiwan University (NTU) placed 69th in the 2025 QS World University Rankings, yet its clinical medicine subject ranking soared to 50th globally, highlighting a significant divergence between institutional prestige and disciplinary strength. According to the 2023 National Science and Technology Council (NSTC) report, Taiwan’s total biomedical research output reached 18,742 papers indexed in Web of Science, accounting for 32.7% of the island’s total scientific publications. This concentration in medicine—nearly one-third of all research—is unusually high compared to the OECD average of 24.1% for health sciences (OECD, 2022, Health at a Glance). For prospective graduate students and their families evaluating institutions, these metrics demand a granular look beyond composite rankings. The following analysis dissects Taiwan’s medical research performance across the four major global ranking systems—QS, Times Higher Education (THE), U.S. News & World Report, and the Academic Ranking of World Universities (ARWU)—to isolate the factors driving high citation impact and clinical output in a system that produces 6.2 biomedical papers per 1,000 capita annually.

The Composite Ranking Landscape: Taiwan’s Position in QS, THE, U.S. News, and ARWU

The four major ranking systems measure universities through different weighted lenses, producing divergent outcomes for Taiwanese institutions. In the 2024 QS World University Rankings, NTU ranked 69th overall, but its position in “Life Sciences & Medicine” rose to 50th, driven by a strong academic reputation score of 82.3/100 in that faculty. Times Higher Education’s 2024 World University Rankings placed NTU at 152nd globally, yet its clinical and health subject ranking jumped to 101–125th band. U.S. News & World Report’s 2023 Best Global Universities ranked NTU 203rd overall, but its “Clinical Medicine” subject ranking reached 87th. ARWU’s 2023 Global Ranking of Academic Subjects placed NTU’s clinical medicine at 76–100th band. This pattern—institutions ranking 50–100 spots lower in overall rankings than in medical subjects—repeats for National Yang Ming Chiao Tung University (NYCU) and Taipei Medical University (TMU). The discrepancy stems from weighting: overall rankings penalize Taiwanese universities for low international faculty ratios (NTU scores 38.7/100 in QS International Faculty Ratio) and smaller endowments, while medical subject rankings emphasize citation impact and research volume, where Taiwan excels.

Clinical Medicine Citation Impact: A Closer Look at NTU and TMU

Citation metrics form the backbone of medical subject rankings, and Taiwan’s top institutions show competitive performance. In the 2023 U.S. News subject ranking for Clinical Medicine, NTU achieved a citation-normalized impact of 1.42 (world average = 1.0), placing it 87th globally. Taipei Medical University (TMU), though ranked 601–800th overall by QS, achieved an even higher normalized citation impact of 1.58 in clinical medicine, securing a 151–200th band in U.S. News. This inverse relationship—lower overall rank but higher citation impact—is noteworthy. According to the 2022 Taiwan Ministry of Education (MOE) report on higher education research output, TMU produced 3,214 clinical medicine papers between 2017 and 2021, with an average of 12.7 citations per paper, compared to the global average of 9.8 for the same field. The field-weighted citation impact (FWCI) for NTU’s medical faculty, as reported by SciVal (2023 data), stood at 1.67, indicating 67% more citations than the world average. For families evaluating schools, this suggests that mid-ranked Taiwanese medical universities deliver research impact that rivals top-100 global institutions, particularly in niche areas like oncology, infectious diseases, and regenerative medicine.

Subject-Level Breakdown: Biomedical Engineering and Public Health

Beyond clinical medicine, two sub-fields show distinct ranking patterns. In ARWU’s 2023 “Biomedical Engineering” subject ranking, NTU placed 51–75th globally, while National Cheng Kung University (NCKU) ranked 101–150th. The public health subject in QS 2024 saw NTU ranked 51–100th, with National Taiwan Normal University (NTNU) and National Sun Yat-sen University also appearing in the 151–200th band. A 2023 analysis by the National Health Research Institutes (NHRI) found that Taiwan’s public health research output grew 8.3% annually from 2018 to 2022, outpacing the global average of 5.1%. However, international collaboration rates for Taiwanese public health papers remain at 34.2%, below the OECD average of 41.7% (OECD, 2022, Science, Technology and Innovation Outlook). This collaboration gap partly explains why Taiwan’s public health rankings lag behind its clinical medicine performance, as many ranking systems assign weight to international co-authorship. For students targeting biomedical engineering, NTU’s strong showing in ARWU (top 75) makes it a viable option, while those interested in public health may find better collaboration opportunities at institutions with established international partnerships, such as National Taiwan University’s Global Health Program.

The Role of Research Funding and Clinical Trial Output

Research funding density directly correlates with ranking performance in medical subjects. The 2023 NSTC report indicates that Taiwan’s total health research expenditure reached NT$34.2 billion (approximately US$1.1 billion), with 62% allocated to universities and 38% to hospitals and research institutes. NTU received NT$6.8 billion (20% of the total), while TMU and NCKU received NT$2.1 billion and NT$1.9 billion respectively. Clinical trial output—a key metric in THE’s clinical subject ranking—shows Taiwan registered 1,847 clinical trials on ClinicalTrials.gov between 2018 and 2023, with 43% conducted at university-affiliated medical centers. The Ministry of Health and Welfare’s 2022 report noted that Taiwan’s clinical trial density (trials per million population) reached 78.3, exceeding Japan’s 62.1 and South Korea’s 54.7. This high trial output boosts citation scores, as clinical trial publications typically receive 2.3 times more citations than non-trial medical papers (NHRI, 2023). For international students, this means Taiwanese universities offer access to active clinical research environments, particularly in oncology trials (which constitute 31% of all registered trials). Some families managing cross-border tuition payments for such programs use channels like Flywire tuition payment to settle fees efficiently.

Regional Comparison: Taiwan vs. Hong Kong, Singapore, and South Korea

A comparative analysis reveals Taiwan’s relative strengths and weaknesses. In THE 2024 Clinical and Health subject ranking, the University of Hong Kong (HKU) ranked 29th, National University of Singapore (NUS) 22nd, and Seoul National University (SNU) 40th, while NTU placed 101–125th. However, when normalized for research output per capita, Taiwan’s performance shifts. According to the 2023 SCImago Institutions Rankings, Taiwan produced 2.1 medical papers per 1,000 researchers, compared to Hong Kong’s 1.6, Singapore’s 1.8, and South Korea’s 1.9. Taiwan’s citation impact per paper in medicine (12.7) also exceeds South Korea (11.4) and approaches Singapore (13.1) (SCImago, 2023). The gap in overall ranking stems primarily from institutional size and international diversity metrics: NTU’s medical faculty has 1,200 full-time researchers versus NUS’s 2,800. The U.S. News 2023 regional ranking for “Best Global Universities in Asia” placed NTU 14th, but its “Clinical Medicine” subject ranking in Asia was 8th, indicating that Taiwan’s medical research punches above its weight in citation-based metrics. For students weighing regional options, Taiwan offers lower tuition (average NT$120,000 per year for medical programs versus HK$421,000 at HKU) while maintaining competitive research output in specialized fields.

Challenges and Future Outlook: International Collaboration and Brain Drain

Despite strong citation performance, two structural challenges threaten Taiwan’s medical ranking trajectory. The first is international collaboration rates: only 38.5% of Taiwan’s medical papers have international co-authors, compared to 52.3% for Singapore and 48.1% for Hong Kong (NSTC, 2023). This metric directly impacts QS and THE subject rankings, which assign 10–15% weight to international research network scores. The second challenge is brain drain: the Ministry of Education reported that 1,247 Taiwanese medical researchers relocated abroad between 2019 and 2022, with 62% moving to the United States and 18% to Singapore. However, a countervailing trend is the rise of international medical programs taught in English. As of 2024, six Taiwanese universities offer English-taught medical degrees, up from two in 2018, attracting 340 international students in the 2023 academic year (MOE, 2024). The government’s “Taiwan Study in Taiwan” initiative, launched in 2022, aims to double international medical enrollment to 800 by 2026. If successful, this could improve international diversity scores in rankings by 3–5 points for NTU and TMU within three cycles. For families, the window for competitive tuition rates and improving international exposure may narrow as these programs scale.

FAQ

Q1: Which Taiwanese university has the highest medical subject ranking globally?

National Taiwan University (NTU) holds the highest medical subject ranking among Taiwanese institutions, placing 50th globally in QS Life Sciences & Medicine 2024 and 87th in U.S. News Clinical Medicine 2023. Taipei Medical University (TMU) follows with a 151–200th band in U.S. News Clinical Medicine, despite ranking 601–800th overall.

Q2: How does Taiwan’s medical research output compare to other Asian countries?

Taiwan produces 2.1 medical papers per 1,000 researchers, higher than Hong Kong (1.6) and South Korea (1.9), but lower than Singapore (1.8) in per-capita terms. However, Taiwan’s citation impact per paper (12.7 citations) exceeds South Korea (11.4) and approaches Singapore (13.1), according to 2023 SCImago data.

Q3: Are English-taught medical programs available in Taiwan?

Yes, as of 2024, six Taiwanese universities offer English-taught medical degrees, including NTU, TMU, and National Cheng Kung University. These programs enrolled 340 international students in 2023, up from 120 in 2018, with tuition averaging NT$120,000 per year—significantly lower than Hong Kong or Singapore programs.

References

• National Science and Technology Council (NSTC). 2023. Taiwan Biomedical Research Output Report 2018–2022.
• OECD. 2022. Health at a Glance 2022: OECD Indicators.
• Ministry of Education (MOE), Taiwan. 2024. Higher Education International Enrollment Statistics.
• SCImago Institutions Rankings. 2023. Research Performance Indicators for Asian Medical Schools.
• U.S. News & World Report. 2023. Best Global Universities: Clinical Medicine Subject Rankings.